2023
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, Su N, Kristufek S, Lundberg D, Bhagchandani S, Ghobrial I, Ghoroghchian P, Johnson J. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology 2023, 18: 184-192. PMID: 36702954, PMCID: PMC10032145, DOI: 10.1038/s41565-022-01310-1.Peer-Reviewed Original ResearchConceptsCombination therapyMultiple myelomaNarrow therapeutic indexMultiple myeloma therapyFree drug combinationFree drug counterpartsMyeloma therapySame doseTherapeutic indexTumor progressionBPD exhibitTherapyProteasome inhibitorsCombination nanomedicinesCancer therapyMonotherapyMyelomaSynergistic ratio
2022
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
Dane E, Belessiotis-Richards A, Backlund C, Wang J, Hidaka K, Milling L, Bhagchandani S, Melo M, Wu S, Li N, Donahue N, Ni K, Ma L, Okaniwa M, Stevens M, Alexander-Katz A, Irvine D. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity. Nature Materials 2022, 21: 710-720. PMID: 35606429, PMCID: PMC9156412, DOI: 10.1038/s41563-022-01251-z.Peer-Reviewed Original ResearchConceptsSTING agonistsRobust T cell activationInnate immune stimulatorsT cell activationTumor rechallengeAnticancer immunityDendritic cellsAgonist deliverySingle doseCyclic dinucleotidesTumor antigensImmune stimulatorImmune memorySolid tumorsEnhanced immunotherapySystemic deliveryTumorsTumor cellsCancer cellsAgonistsImmunityDeliveryCellsActivationCleavable linker
2021
Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Bhagchandani S, Johnson J, Irvine D. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. Advanced Drug Delivery Reviews 2021, 175: 113803. PMID: 34058283, PMCID: PMC9003539, DOI: 10.1016/j.addr.2021.05.013.Peer-Reviewed Original ResearchConceptsVaccine adjuvantsImidazoquinoline derivativesToll-like receptor 7Candidate vaccine adjuvantsSkin cancer treatmentBroad therapeutic utilityTLR7 toleranceTopical antiviralsImmunomodulatory agentsReceptor 7Systemic administrationPoor pharmacokinetic propertiesTherapeutic utilitySuccessful clinical translationSynthetic agonistsAntiviral formulationsInfectious diseasesPharmacokinetic propertiesCancer treatmentBroad expression profileAdjuvantClinical translationBiodistributionExpression profilesTherapeutics
2020
Trends in Therapeutic Conjugates: Bench to Clinic
Rudra A, Li J, Shakur R, Bhagchandani S, Langer R. Trends in Therapeutic Conjugates: Bench to Clinic. Bioconjugate Chemistry 2020, 31: 462-473. PMID: 31990184, DOI: 10.1021/acs.bioconjchem.9b00828.Peer-Reviewed Original Research
2018
Towards an arthritis flare-responsive drug delivery system
Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter K, Sherman N, Amirault J, Wang Y, Riegel L, He X, Rui T, Valic M, Vemula P, Miranda O, Levy O, Gravallese E, Aliprantis A, Ermann J, Karp J. Towards an arthritis flare-responsive drug delivery system. Nature Communications 2018, 9: 1275. PMID: 29615615, PMCID: PMC5882944, DOI: 10.1038/s41467-018-03691-1.Peer-Reviewed Original ResearchConceptsTriamcinolone acetonideInflammatory arthritisArthritis activityFree triamcinolone acetonideIA therapyArthritic miceRheumatoid arthritisArthritis flaresLocal drug delivery methodSingle doseDrug delivery methodsSynovial fluidDrug delivery approachEquivalent doseLocal deliveryArthritisDoseDelivery approachDrug delivery systemsTreatmentDelivery methodsDelivery systemPatientsTherapyIA severity
2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer
Levy O, Brennen W, Han E, Rosen D, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani S, Joshi N, Bhowmick N, Denmeade S, Isaacs J, Karp J. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials 2016, 91: 140-150. PMID: 27019026, PMCID: PMC4824400, DOI: 10.1016/j.biomaterials.2016.03.023.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCells, CulturedDrug Delivery SystemsHumansLactic AcidMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, NudePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProdrugsProstateProstate-Specific AntigenProstatic NeoplasmsConceptsMesenchymal stem cellsDelivery platformDrug delivery platformSystemic delivery platformHuman mesenchymal stem cellsCell-based deliveryGenetic engineeringProstate cancerDisseminated prostate cancerPCa cell linesProstate-specific antigenProstate cancer researchLoaded cellsMicroparticlesStem cellsPromising approachPCa xenograftsMetastatic PCaPlatformCancer sitesAnti-cancer drugsPotential treatmentSpecific antigenCancer growthTumor growth